Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sucampo Pharmaceuticals has announced that its wholly owned subsidiary, Sucampo Pharma Europe, filed a marketing authorization application in Switzerland for Amitiza for the indication of chronic idiopathic constipation in adults.
Subscribe to our email newsletter
The marketing authorization application (MAA) was filed with Swissmedic by Sucampo Pharmaceuticals’s branch office in Basel, Switzerland.
The submission is part of the ongoing development of Amitiza 24mcg which was first launched in the US in April 2006 for the treatment of chronic idiopathic constipation in adults.
In May 2008, Amitiza 8mcg was launched for the treatment of irritable bowel syndrome with constipation in adult women. Earlier in 2008, MAAs were filed in nine European countries for chronic idiopathic constipation in adults at 24mcg and are currently under review.
Ryuji Ueno, founder, chairman and CEO of Sucampo, said: “This application is a continuation of these efforts as well as an ongoing expansion of our European operations.”